4//SEC Filing
Murphy Matthew B. 4
Accession 0001808805-25-000026
CIK 0001808805other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:52 PM ET
Size
386.1 KB
Accession
0001808805-25-000026
Insider Transaction Report
Form 4
Murphy Matthew B.
General Counsel
Transactions
- Award
Stock Option (Right to Buy)
2025-03-03+160,000→ 160,000 totalExercise: $1.24Exp: 2035-03-03→ Common Stock (160,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025.
Issuer
Nautilus Biotechnology, Inc.
CIK 0001808805
Entity typeother
Related Parties
1- filerCIK 0001865778
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:52 PM ET
- Size
- 386.1 KB